Joe Patterson, Author at Friends of Cancer Research

Insights from the July 25, 2024 Meeting of the Oncology Drug Advisory Committee

| July 26, 2024

Emerging data from clinical trials evaluating the use of immune checkpoint inhibitors (ICI) as part of adjuvant, neoadjuvant, and perioperative regimens indicate improved outcomes for patients with resectable non-small cell lung cancer (NSCLC), including early data suggesting a survival benefit. Perioperative treatment encompasses the entire period surrounding surgery, with neoadjuvant therapy administered before surgery and…

Digital PATH Project looks to the future of oncology

| March 19, 2024

Digital and computational pathology platforms have the potential to provide more precise and novel diagnostic insights to inform treatment decision making and, ultimately, improve patient outcomes. Friends of Cancer Research (Friends) is leading a new research partnership, the Digital and Computational Pathology Tool Harmonization (Digital PATH) Project, to support robust development of digital and computational pathology platforms for use in oncology drug development.

Critical Findings from Friends HRD Harmonization Project

| March 12, 2024

Homologous Recombination Deficiency (HRD) is a complex biomarker that can help identify patients likely to respond to certain therapies. Friends of Cancer Research’s (Friends) HRD Harmonization Project Harmonization Project is a unique research partnership to find alignment among different assays that measure HRD, to support its use as a biomarker in clinical research and care, and to serve as a foundational…

Watch Now: Friends of Cancer Research Annual Meeting 2023

| November 21, 2023

On November 14, 2023, Friends of Cancer Research hosted our 16th Annual Meeting in Washington, D.C. Discussions at the meeting were the culmination of three working groups led by the organization over the past year, which collaboratively proposed solutions for three key challenges in oncology drug development: dose-finding in early phase trials, incorporating pragmatic elements in clinical trials, and using data from academic-led studies for regulatory decision-making.

Watch Now: Expediting Drug Development – Use of ctDNA as an Early Endpoint

| July 28, 2022

On Wednesday, July 20, Friends of Cancer Research (Friends) hosted a meeting titled “Expediting Drug Development: Use of ctDNA as an Early Endpoint.” Welcoming everyone, Jeff Allen, President & CEO of Friends, provided updates regarding Friends’ ctDNA for Monitoring Treatment Response (ctMoniTR) project , a unique collaboration exploring whether changes in ctDNA levels can indicate clinical…

Author: Joe Patterson